Related Experiment Videos
[Cardiac complications in patients with schizophrenic disorders]
1Klinik für Psychiatrie und Psychotherapie, Klinikum Niederberg, Robert-Koch-Strasse 2, 42549 Velbert. Meincke@Klinikum-Niederberg.de
Insights
Patients with schizophrenia have higher cardiac risks due to lifestyle and antipsychotic side effects. Regular monitoring and interventions are crucial for managing cardiovascular health in schizophrenia patients.
Area of Science:
- Cardiology
- Psychiatry
- Pharmacology
Context:
- Schizophrenia patients face elevated cardiac morbidity and mortality.
- Cardiovascular risks are linked to lifestyle and reduced prevention program adherence.
- Atypical antipsychotics contribute to obesity, hypertriglyceridemia, and diabetes.
Purpose:
- To highlight the need for standardized cardiovascular risk assessment in schizophrenia patients.
- To emphasize the importance of managing metabolic and cardiac side effects of antipsychotic medications.
- To advocate for integrated care including medication adjustment, dietary counseling, and behavioral therapies.
Summary:
- Schizophrenia is associated with increased cardiovascular disease, partly due to lifestyle factors and poor adherence to preventive care.
- Atypical antipsychotics can worsen metabolic parameters like obesity, hypertriglyceridemia, and diabetes, necessitating regular monitoring.
- Cardiac complications, including QT-prolongation and arrhythmias, can arise from antipsychotic treatment, requiring careful risk factor evaluation.
Impact:
- Standardized cardiovascular monitoring can lead to early detection and management of risks in schizophrenia patients.
- Personalized treatment strategies, including medication modulation and lifestyle interventions, can improve cardiac outcomes.
- Addressing both metabolic and direct cardiac side effects of antipsychotics is vital for long-term patient well-being.
Abstract:
It is well known, that patients with schizophrenia exhibit increased rates of cardiac morbidity and mortality. Frequent cardiovascular diseases are only partially explained by lifestyle, inactivity, dietary habits and nicotine abuse, but also by reduced compliance in prevention programs. On the other hand, it has been shown that particularly atypical antipsychotic agents are differentially responsible for high rates of obesity, hypertriglyceridemia, and diabetes. Therefore, a standardized evaluation of corresponding parameters is indicated in every patient. If needed, modulation of the medication regimen has to be performed. Additionally, a dietary counselling of the patient and his family should be offered. Besides pharmacological approaches to normalize dyslipidemia, specific behavioural therapy programmes are an option that may alter metabolic parameters. Threatening cardiac complications in long-term treatment of schizophrenia may also be the result of direct side effects under treatment with antipsychotics, like QT-prolongation triggering major arrhythmias. For prevention, predisposing risk factors like electrolyte disturbances, pre-existing cardiac diseases, co-medication with QT prolonging drugs and medication with potential cytochrome P450 interaction have to be taken into consideration.
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Schizophrenia
Coronary Artery Disease III: Clinical Manifestations
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Rheumatic Heart Disease I: Introduction